With the recent approval by both the FDA and EMEA of aliskiren as the first renin inhibitor for clinical use, the question is to what degree this drug differs from the existing renin-angiotensin system blockers, i.e., the ACE-inhibitors and the angiotensin II type 1 (AT 1 ) receptor blockers. The answer may lie in the so-called (pro)renin receptor.
This receptor binds both renin and its inactive precursor, prorenin, and may thus be responsible for the uptake of (pro)renin (a term denoting both renin and prorenin) at tissue sites. Such uptake is important for local angiotensin production. Interestingly, prorenin binding to the receptor results in a conformational change of the molecule, allowing prorenin to display full enzymatic activity. Given the much higher levels of prorenin in blood (up to ten-fold the levels of renin), 1 this receptor binding-induced prorenin activation therefore might explain not only why we have so much prorenin, but also how prorenin exerts its effects without the existence of prorenin-converting enzymes at tissue sites. 2 Aliskiren, as a renin inhibitor, will obviously block receptor-activated prorenin, and as such is an ideal drug to suppress tissue angiotensin generation. 3 Surprisingly, the (pro)renin receptor also induces signalling following (pro)renin binding. 4, 5 Since this occurred independently of angiotensin generation, renin and/or prorenin may act as agonists of this receptor. The receptor is present in virtually every cell of the body, and at these sites is largely located intracellularly. In fact, as outlined by Michael Bader in this issue of the Renin Report, the C-terminal part of the receptor had been found earlier in association with vacuolar H + -ATPase, a protein involved in the H + translocation across membranes, both intracellular and on the cell surface. 6 The (pro)renin binding N-terminal part of the receptor can be released.
On the one hand, this association with vacuolar H + -ATPase might be highly relevant given the fact that low pH helps prorenin to undergo the conformational change that results in its activation. 7 On the other hand, it is possible that the N-terminal (pro)renin-binding part has functions that are totally unrelated to H + translocation. Bader even suggests that the (pro)renin-(pro)renin receptor complex activates yet another receptor. This is reminiscent of the aldosterone-mineralocorticoid receptor complex acting as a transcription factor in the nucleus. In agreement with this concept, Re and Cook have recently proposed that (pro)renin is an 'intracrine' enzyme with both extracellular signalling capabilities and intracellular functions. 8 Time will tell whether this is true, and to what degree aliskiren interferes with these unknown functions of (pro)renin. If so, renin inhibitors might exert additional effects on top of RAS blockade.
